Literature DB >> 20445403

NIAID/NIH radiation/nuclear medical countermeasures product research and development program.

Nathaniel Hafer1, David Cassatt, Andrea Dicarlo, Narayani Ramakrishnan, Joseph Kaminski, Mai-Kim Norman, Bert Maidment, Richard Hatchett.   

Abstract

One of the greatest national security threats to the United States is the detonation of an improvised nuclear device or a radiological dispersal device in a heavily populated area. The U.S. Government has addressed these threats with a two-pronged strategy of preventing organizations from obtaining weapons of mass destruction and preparing in case an event occurs. The National Institute of Allergy and Infectious Diseases (NIAID) contributes to these preparedness efforts by supporting basic research and development for chemical, biological, radiological, and nuclear countermeasures for civilian use. The Radiation Countermeasures Program at NIAID has established a broad research agenda focused on the development of new medical products to mitigate and treat acute and long-term radiation injury, promote the clearance of internalized radionuclides, and facilitate accurate individual dose and exposure assessment. This paper reviews the recent work and collaborations supported by the Radiation Countermeasures Program.

Entities:  

Mesh:

Year:  2010        PMID: 20445403     DOI: 10.1097/HP.0b013e3181bbc4df

Source DB:  PubMed          Journal:  Health Phys        ISSN: 0017-9078            Impact factor:   1.316


  13 in total

1.  Rapid and High-Throughput Detection and Quantitation of Radiation Biomarkers in Human and Nonhuman Primates by Differential Mobility Spectrometry-Mass Spectrometry.

Authors:  Zhidan Chen; Stephen L Coy; Evan L Pannkuk; Evagelia C Laiakis; Adam B Hall; Albert J Fornace; Paul Vouros
Journal:  J Am Soc Mass Spectrom       Date:  2016-07-08       Impact factor: 3.109

2.  Decreasing the adverse effects of cancer therapy: an NCI Workshop on the preclinical development of radiation injury mitigators/protectors.

Authors:  Julie L Ryan; Sunil Krishnan; Benjamin Movsas; C Norman Coleman; Bhadrasain Vikram; Stephen S Yoo
Journal:  Radiat Res       Date:  2011-09-01       Impact factor: 2.841

3.  NRF2 mitigates radiation-induced hematopoietic death.

Authors:  John P Chute
Journal:  J Clin Invest       Date:  2014-02-24       Impact factor: 14.808

4.  Insulin-like growth factor 1 mitigates hematopoietic toxicity after lethal total body irradiation.

Authors:  Dunhua Zhou; Divino Deoliveira; Yubin Kang; Seung S Choi; Zhiguo Li; Nelson J Chao; Benny J Chen
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-09-25       Impact factor: 7.038

5.  Liquid Chromatography-Mass Spectrometry-Based Metabolomics of Nonhuman Primates after 4 Gy Total Body Radiation Exposure: Global Effects and Targeted Panels.

Authors:  Evan L Pannkuk; Evagelia C Laiakis; Kirandeep Gill; Shreyans K Jain; Khyati Y Mehta; Denise Nishita; Kim Bujold; James Bakke; Janet Gahagen; Simon Authier; Polly Chang; Albert J Fornace
Journal:  J Proteome Res       Date:  2019-03-18       Impact factor: 4.466

Review 6.  Saving normal tissues - a goal for the ages.

Authors:  Angela M Groves; Jacqueline P Williams
Journal:  Int J Radiat Biol       Date:  2019-03-29       Impact factor: 2.694

7.  The NIAID Radiation Countermeasures Program business model.

Authors:  Nathaniel Hafer; Bert W Maidment; Richard J Hatchett
Journal:  Biosecur Bioterror       Date:  2010-12

8.  Exposure to ionizing radiation reveals global dose- and time-dependent changes in the urinary metabolome of rat.

Authors:  Tytus D Mak; John B Tyburski; Kristopher W Krausz; John F Kalinich; Frank J Gonzalez; Albert J Fornace
Journal:  Metabolomics       Date:  2014-12-20       Impact factor: 4.290

9.  Scientific research and product development in the United States to address injuries from a radiation public health emergency.

Authors:  Andrea L DiCarlo
Journal:  J Radiat Res       Date:  2021-09-13       Impact factor: 2.724

Review 10.  Acute Radiation Syndrome and the Microbiome: Impact and Review.

Authors:  Brynn A Hollingsworth; David R Cassatt; Andrea L DiCarlo; Carmen I Rios; Merriline M Satyamitra; Thomas A Winters; Lanyn P Taliaferro
Journal:  Front Pharmacol       Date:  2021-05-18       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.